Home visits ↑/NC knowledge about hygiene and sanitation, ↑ hand-washing, ↑ water quality, ↓/NC diarrheal morbidity, ↓ intestinal parasite prevalence ↑/NC knowledge about hygiene and sanitation, ↑ hand-washing, ↑ water quality, ↓/NC diarrheal morbidity, ↓ intestinal parasite prevalence ↓ maternal mortality, ↑/NC knowledge about hygiene and sanitation, ↑/NC hand-washing, ↑ water quality, NC waste disposal, ↓/NC diarrheal morbidity, ↓ intestinal parasite prevalence ↑/NC knowledge about hygiene and sanitation, ↑ hand-washing, ↑ water quality, ↓/NC diarrheal morbidity, ↓ intestinal parasite prevalence
Wood, Susan F.; Dor, Avi; Gee, Rebekah E.; Harms, Alison; Mauery, D. Richard; Rosenbaum, Sara J.; Tan, Ellen (15 June 2009). Women's health and health care reform: the economic burden of disease in women'. D. Richard. Washington DC: George Washington University, School of Public Health and Health Services, Jacobs Institute of Women's Health. Retrieved 17 July 2016.
Women's reproductive and sexual health has a distinct difference compared to men's health. Even in developed countries pregnancy and childbirth are associated with substantial risks to women with maternal mortality accounting for more than a quarter of a million deaths per year, with large gaps between the developing and developed countries. Comorbidity from other non reproductive disease such as cardiovascular disease contribute to both the mortality and morbidity of pregnancy, including preeclampsia. Sexually transmitted infections have serious consequences for women and infants, with mother-to-child transmission leading to outcomes such as stillbirths and neonatal deaths, and pelvic inflammatory disease leading to infertility. In addition infertility from many other causes, birth control, unplanned pregnancy, unconsensual sexual activity and the struggle for access to abortion create other burdens for women.
Changes in the way research ethics was visualised in the wake of the Nuremberg Trials (1946), led to an atmosphere of protectionism of groups deemed to be vulnerable that was often legislated or regulated. This resulted in the relative underrepresentation of women in clinical trials. The position of women in research was further compromised in 1977, when in response to the tragedies resulting from thalidomide and diethylstilbestrol (DES), the United States Food and Drug Administration (FDA) prohibited women of child-bearing years from participation in early stage clinical trials. In practice this ban was often applied very widely to exclude all women. Women, at least those in the child-bearing years, were also deemed unsuitable research subjects due to their fluctuating hormonal levels during the menstrual cycle. However, research has demonstrated significant biological differences between the sexes in rates of susceptibility, symptoms and response to treatment in many major areas of health, including heart disease and some cancers. These exclusions pose a threat to the application of evidence-based medicine to women, and compromise to care offered to both women and men.